CanSino Biologics Inc. reported audited consolidated earnings results for the six months ended June 30, 2021. For the period, the company reported revenue of RMB 2,061.455 million against nil a year ago. Operating profit was RMB 802.332 million against operating loss of RMB 123.001 million a year ago. Profit and total comprehensive income for the period was RMB 937.133 million against loss and total comprehensive expense for the period of RMB 102.201 million a year ago. Earnings per basic and diluted share was RMB 3.79 against loss per basic and diluted share of RMB 0.46 a year ago.